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Hepatitis A is a disease of worldwide distribution which occurs in endemic and epidemic form
and is transmitted primarily by person-to-person contact through the fecal-oral route. Com-
mon source epidemics due to contamination of food are relatively common, and water-borne
epidemics have been described less frequently. The presumed etiologic agent ofhepatitis A has
now been visualized by immune electron microscopic (IEM) techniques in early acute-illness-
phase stools of humans with hepatitis A as well as in chimpanzees experimentally infected with
material known to contain hepatitis A virus. In addition, several new serologic tests for the de-
tection of antibody against hepatitis A virus have been described. These include complement
fixation and immune adherence techniques. Current data suggest that hepatitis A is caused by a
single viral agent lacking the morphologic heterogeneity of hepatitis B viral components and
that there may be relative antigenic homogeneity between strains of virus recovered from
various parts of the world. Serologic studies to date also indicate that hepatitis A virus is not a
major contributing cause in post-transfusion hepatitis.
BACKGROUND
The historical roots of infectious hepatitis as a distinct clinical entity go back, in
the United States and Europe, to the late 18th and early 19th centuries, when reports
of scattered outbreaks of a syndrome called "infectious," "epidemic," or "catar-
rhal" jaundice began to appear in the literature. Blumer, in 1923, described 63 epi-
demics of this disease which occurred in the United States between 1812 and 1920
(1). He differentiated the illness from Weil's disease and characterized it as a disease
of childhood and early adult life, having an incubation period of up to 28 days, spread
by person-to-person contact, and with greatest incidence in fall and winter months.
Williams, in his report of 1923 on epidemicjaundice in New York state, corroborated
the findings of Blumer and suggested a viral etiology (2). These early observations es-
tablished the clinical, epidemiologic, and etiologic basis for a major form of viral he-
patitis. In 1947, MacCallum proposed that this entity be called "hepatitis A" to dis-
tinguish it clearly from homologous serumjaundice or "hepatitis B" (3).
The existence of two distinct and separate viral etiologies for hepatitis A and B was
firmly established during World War II in studies utilizing human volunteers (4-6).
The disease was induced through oral feeding of subjects with serum and stool
filtrates from acutely ill patients. Existence of homologous immunity was
demonstrated through failure to reinduce hepatitis in convalescent volunteers when
they were rechallenged with the same inoculum. However, if these individuals were
rechallenged with serum or plasma known to cause hepatitis B, clinical hepatitis
recurred. These data indicated a lack of cross immunity between the two forms ofin-
fection and thus the existence oftwo etiologic agents.
The human volunteer studies described above were confirmed and expanded by an
extensive series of investigations in children, carried out at the Willowbrook State
School in New York (7, 8). These studies revealed that the hepatitis A virus was
present in feces during the incubation period of the disease, in some cases as early as
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2 to 3 weeks prior to onset ofjaundice. The shorter incubation period ofhepatitis A in
contrast to hepatitis B by either oral or percutaneous inouclation was experimentally
confirmed, and a pedigreed serum pool containing hepatitis A virus, known as the
MS-1 pool, was established. The virus contained in this pool has been commonly
referred to as the MS-1 strain of hepatitis A virus. This material was used exten-
Iively in further prison volunteer studies at Joliet, Ill., supported by the U.S. Army,
which resulted, as will be described later, in the first visualization of the hepatitis A
virus.
EPIDEMIOLOGY
Hepatitis A is a disease of worldwide distribution which occurs in both endemic
and epidemic form. In common with patterns of poliomyletis before the advent of
polio vaccine, the disease classically occurs in children with a demonstrable effect of
socioeconomic and sanitation level on overall and agespecific incidence. Thus, in
developing areas of the world and in communities in the United States where socio-
economic level is low and sanitation poor, epidemics appear to be cyclic, affecting in-
fants and young children born during interepidemic periods. Since immunity follow-
ing infection is of long duration, instances of disease in adolescents and adults are
rare and usually involve in-migrant susceptibles. As with polio, childhood infection
rates are high with the majority of infections being subclinical and clinical disease
mild. In areas of higher socioeconomic level and where good sanitation practice
exists, environmental barriers and increased host resistance may prevent infection in
early childhood. In such areas, there are increased numbers of cases in adults. The
geographic aggregation ofsuch susceptibles has resulted in outbreaks in military bar-
racks, colleges, universities, and summer camps. Clinical disease tends to be some-
what more severe in these older age groups and incidence of subclinical infection
lower. For the United States as a whole, compilation ofnational morbidity data since
1952 indicates that type A hepatitis incidence followed a minor cyclic phase with
yearly fall and winter peaks. Beginning in 1966, however, this seasonal cyclicity has
tended to disappear, and, as shown in Fig. 1, yearly incidence had, by 1973, appeared
to reach a plateau.
Man is the primary reservoir of the hepatitis A virus, although chimpanzees have
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FIG. 1. Incidence of viral hepatitis by 4-week period, U.S. 1966-1974 (source: U.S. Department of
Health, Education, and Welfare, Public Health Service, Center for Disease Control, Hepatitis Sur-
veillance Report Number 37, Atlanta, Ga., June 1975).
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been shown to transmit assumed type A disease to human contacts (9-11) and can be
experimentally infected with the virus (12). The most common route oftransmission
of hepatitis A is by person-to-person contact through the fecal-oral route, and fecal
carriers of the virus who are asymptomatic or are in the preclinical stages ofdisease
are major contributors to spread ofinfection. In addition, common source epidemics
due to contamination of water and milk have been described, and food-borne out-
breaks ofhepatitis A are relatively common. Among specific food items incriminated
have been raw oysters and clams, cold meat, green salad, and bakery items.
From the military point of view, the implications of the above epidemiologic fea-
tures of hepatitis A are evident. The aggregation of large numbers of susceptible
recruits into barracks and camps with common eating and sleeping facilities
increases the likelihood of dissemination of infection by preclinical-stage fecal car-
riers of the virus. Similarly, assignment of troops abroad to areas of hepatitis A
hyperendemicity provides multiple possibilities for contact with asymptomatic virus
carriers. In the military context, food-borne epidemics constitute a particular
hazard, the latest large-scale incident having occurred in 1975 at a naval station in
Southern California (13).
RECENT ADVANCES
In recent years there have been numerous attempts to isolate and characterize the
hepatitis A virus in cell culture systems and in nonhuman primate animal models. To
date, all attempts at in vitro propagation ofthe virus have ended in failure. More suc-
cessful were attempts, during the mid-1960's and early 1970's, to reproducibly
induce presumed hepatitis A in marmosets (South American monkeys). In 1965,
Deinhardt and colleagues reported induction and subpassage of enzymatically and
histologically typical hepatitis in several subspecies of these animals (14). One
serially transmissible agent, named "Barker" agent after a surgeon who developed
acute viral hepatitis and whose acute-illness-phase serum induced hepatitis in the
marmosets, was initially advanced as a possible hepatitis A candidate agent. In a
separate series of experiments, Holmes, Deinhardt, and colleagues were able to in-
duce hepatitis and subpassage the infection in marmosets inoculated with acute-ill-
ness-phase sera from the volunteers in the Joliet prison experiments mentioned
previously who developed hepatitis following inoculation with the MS-1 strain of he-
patitis A virus (15, 16). Both Lorenz and colleagues, using specimens from the United
States (17), and Mascoli and co-workers, using specimens from cases of presumed
hepatitis A in Costa Rica (18), were able to confirm the susceptibility of marmosets
(specifically of the species Saguinus mystax) to infection. In none ofthe foregoing ex-
periments, however, was a viral agent actually visualized. It was not until 1973 that
the presumed etiologic agent was actually visualized by electron microsocpic immune
aggregation techniques.
The technique of immune electron microscopy (IEM) for direct observation of the
interaction between viruses and their specific homologous serum antibodies was first
described in 1941 (19) and successfully used by Kapikian and colleagues in 1972 for
recovery of a specific enteric virus, "Norwalk agent," shown to be etiologically
responsible for infectious nonbacterial gastroenteritis (20). In 1973, Feinstone and
colleagues reported visualization of viruslike particles in the early acute illness phase
stools of Joliet prison volunteers who had developed hepatitis following previously
described inoculations of the MS-1 strain of hepatitis A virus (21). Soon thereafter,
in a report by Gravelle and co-workers (22), morphologically identical viruslike parti-
cles were recovered from acute-illness-phase stools from individuals acquiring hepa-
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FIG. 2. Hepatitis A-associated viral like particles visualized by the IEM technique.
titis during a common source epidemic oftype A disease in Arizona. As described by
both groups, these particles are spheres of approximately 27-nm diameter. Figure 2
shows a characteristic group of particles aggregated by convalescent phase serum
from a patient with antecedent hepatitis A. The halos surrounding the particles
represent specific hepatitis A antibody interacting with virus. Utilizing the ability of
the IEM procedure to detect serum antibody as well as antigen, both Feinstone and
Gravelle and co-workers detected antibody seroconversions to the particles between
preinoculation and convalescent-phase sera in prison volunteers developing hepatitis
after inoculation with the MS-i strain of virus or rises in titer of serum antibody
between acute-illness-phase and convalescent sera from cases of hepatitis A from
other sources. Both groups failed to detect similar serum antibody rises from cases of
hepatitis B.
In an attempt to examine possible infectivity associated with these particles, May-
nard and colleagues were able to induce and successfully subpassage enzymatically
and histologically confirmed hepatitis in chimpanzees inoculated with human stool
filtrates containing the particles (12). Animals excreted morphologically identical
particles during the early acute stage of hepatitis and developed serum antibody
directed against the particles, further supporting the inference that the particles
themselves, now referred to as hepatitis A antigen (HA Ag), constitute the virus of
hepatitis A. The link between HA Ag and experimentally induced hepatitis A in
marmosets was provided in a collaborative study between the Center for Disease
Control, Food and Drug Administration, and National Institutes of Health, in which
S. mystax marmosets developing hepatitis after inoculation with the MS-i strain of
hepatitis A virus developed antibody seroconversions to HA Ag (23). In addition,
liver homogenates from animals sacrificed in the acute stage of infection contained
HA Ag. Provost and colleagues have also recovered 27-nm-diameter viruslike parti-
cles from the livers ofS. mystax marmosets which developed hepatitis after inocula-
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tion with specimens from individuals acutely ill with hepatitis A in Costa Rica (24).
Krugman and co-workers have demonstrated that children developing hepatitis A in
the Willowbrook studies developed convalescent-phase antibody against these parti-
cles, thus relating the Costa Rican-derived particles as well as the previously
described classes of HA Ag to MS-l hepatitis A (25).
Using IEM techniques with HA Ag as antigen source to examine the possible rela-
tionship of Barker agent-induced marmoset hepatitis to hepatitis A, it has been ob-
served that antibody seroconversions to HA Ag do not occur in animals infected with
Barker agent (26). These data indicate that the Barker agent is not related to hepa-
titis A.
Of major importance has been the development of several additional laboratory
techniques for the diagnosis and seroepidemiologic investigation of hepatitis A.
Hilleman and colleagues have recently reported development ofcomplement fixation
and immune adherence tests for detection ofhepatitis A antigen and antibody, utiliz-
ing HA Ag purified from the livers ofmarmosets infected with hepatitis A virus (27).
Utilizing immune adherence, they presented preliminary data indicating that ap-
proximately 30% of adults from a small sample of American workers and blood
donors were hepatitis A antibody positive, in contrast to 85% in a small sample of
adults in rural Costa Rica. They were also able to characterize 24 commercial lots of
immune serum globulin in regard to hepatitis A antibody content. Further develop-
ment of the marmoset as a source of diagnostic reagents for hepatitis A antibody
testing has, however, been severely limited by the general unavailability ofthese ani-
mals. The recent success ofworkers at the National Institutes of Health in purifying
HA Ag from human stool for use as reagent in immune adherence testing suggests
another possible source of reagent material. However, the logistic difficulty of ob-
taining sufficient early acute-illness-phase stool on a regular basis from hepatitis
patients may severely limit the general availability of this material. Hollinger and
colleagues have recently described adaptation of radioimmune assay techniques for
detection ofhepatitis A antigen and antibody, utilizing antigen purified from stool of
infected chimpanzees (28). It is hoped that the chimpanzee may provide a more re-
producible source ofhepatitis. A diagnostic reagents until a suitable in vitro cell cul-
ture system for propagation ofthe virus is found.
Hepatitis A antigen has now been found in stools from naturally occurring cases of
hepatitis A in several areas of the United States, ranging from Georgia to Arizona,
California, and Alaska. Dienstag and co-workers were able to recently demonstrate
the particles in stool ofnaval recruits involved in a large foodborne outbreak ofhepa-
titis A in San Diego (13). In addition to the particles recovered by Provost et al. from
Costa Rican cases (24), Locarnini and colleagues have recovered HA Ag from acute
cases ofhepatitis A in Australia (29). The morphologic and immunologic similarity of
the various classes of particles referred to as HA Ag, together with the consistency
in worldwide epidemiologic patterns for the disease, suggest that hepatitis A is
caused by a single viral agent lacking theheterogeneity ofhepatitis B virus structural
components. It seems reasonable to infer that there will be little major antigenic
heterogeneity between strains of virus recovered from different geographic areas,
thus accounting for the passive protection conferred by United States-derived im-
mune serum globulin in other parts oftheworld.
From the military viewpoint, risk of infection should be viewed within the context
of enteric transmission, since the viremic state for hepatitis A, as with polio, is
presumed to be transient. Recent serologic studies by Alter et al. (30) and Feinstone
and colleagues (31) indicate that non-hepatitis B-associated post-transfusion hepa-
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titis is also not associated with hepatitis A. This presumed lack of a hepatitis A vi-
remic carrier state also has significant implications for the possible early develop-
ment ofhepatitis A vaccines. Unlike hepatitis B vaccine, which can be produced from
human hepatitis B antigen carriers without requirement for in vitro cultivation ofthe
virus, production of a hepatitis A vaccine will most probably require a breakthrough
in technology for in vitro replication ofhepatitis A virus.
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